Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19832962 | 0.80 | LMNA (0.35) | MEN1KMT2ATDP1ESR1ESR2 | |
| SCHEMBL19832839 | 0.76 | TDP1 (0.47) | MEN1KMT2ATDP1ESR1CYP3A4 | |
| SCHEMBL19833124 | 0.75 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL23119099 | 0.72 | TP53 (0.35) | ALDH1A1MEN1KMT2ATDP1ESR1 | |
| SCHEMBL22898346 | 0.71 | GABRA2 (0.42) | — | |
| SCHEMBL12054100 | 0.69 | ESR1 (0.46) | MEN1KMT2ATDP1ESR1ESR2 | |
| SCHEMBL20459109 | 0.69 | TSHR (0.45) | KMT2AESR1ESR2CYP3A4TSHR | |
| SCHEMBL19483142 | 0.68 | SCN5A (0.44) | KMT2AESR1ESR2 | |
| SCHEMBL12251273 | 0.68 | ALDH1A1 (0.45) | ALDH1A1MEN1KMT2ATDP1ESR1 | |
| SCHEMBL14734279 | 0.67 | ESR1 (0.31) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180028660-A1 | DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180028660-A1 | DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST | PPARG, PPARA, DGAT1 | ALDH1A1 585/4885MEN1 4649/4885KMT2A 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.